Original Article

Expression of E6, p53 and p21 proteins and physical state of HPV16 in cervical cytologies with and without low grade lesions

Diana K Jiménez Tagle1, Daniel Hernández Sotelo2, Berenice Illades-Aguiar2, Marco A Leyva-Vazquez2, Eugenia Flores Alfaro3, Yaneth Castro Coronel1, Oscar del Moral Hernández2, Luz del Carmen Alarcón Romero1

1Laboratorio de Investigación en Citopatología e Histoquímica, 2Laboratorio de Biomedicina Molecular, 3Laboratorio de Epidemiología Molecular, Unidad Académica de Ciencias Químico Biológicas Universidad Autónoma de Guerrero Avenida Lázaro Cárdenas, Ciudad Universitaria, Chilpancingo, Guerrero, México. C.P. 39090, México

Received October 15, 2013; Accepted November 21, 2013; Epub January 15, 2014; Published January 30, 2014

Abstract: The aim of this study was to determine the correlation between expression of HPV16 E6, p53 and p21 proteins and the physical state of HPV16 in cervical cytologies without squamous intraepithelial lesions (Non-SIL) and with low grade squamous intraepithelial lesions (LSIL), both with HPV16 infection. 101 liquid-based cytological samples were analyzed. 50 samples were without squamous intraepithelial lesions (Non-IL) and 51 samples of low grade squamous intraepithelial lesions (LSIL), both with HPV16 infection. HPV16 infection was determined by PCR-RFLP, and the physical state of HPV16 by in situ hybridization with tyramide-amplification. The expression of E6, p53 and p21 proteins was evaluated by immunocytochemistry. The expression of HPV16 E6 protein was significantly higher in LSIL that in Non-SIL samples (p=0.006). We found a significant correlation between E6 expression and the physical state of HPV16 in Non-SIL (p=0.049). Our results suggest that high expression of E6 in LSIL is an early event of cervical carcinogenesis and perhaps can be used as an early marker.

Keywords: E6, p53, p21, HPV16, cervical cancer, LSIL, physical state, liquid-based cytological, immunocytochemistry, in situ hybridization

Introduction

Cervical cancer is characterized by the progression through well characterized squamous intraepithelial lesions (SIL) of the cervix. Based on cytopathologic characteristics, these lesions are divided into low grade (LSIL) and high grade (HSIL), and invasive cervical cancer [1]. Cervical cancer is a multistep process that slowly develops upon persistent infection with oncogenic types of human papillomavirus (HPV) [2, 3]. In Mexico, HPV16 is the most frequent genotype found in cervical cancer [4]. Moreover, HPV16 is one of the most frequent genotypes found in LSIL, HSIL and in women without SIL [5].

HPV16 genome encodes two oncoproteins, E6 and E7. Both proteins are able to cause transformation of the host cell [6]. The E6 protein binds to p53 tumor suppressor and cause its degradation by 26S proteasome, resulting in its inactivation and the impairment of p53-induced cellular apoptosis [7]. Expression of E6 has been proposed as a useful diagnostic and/or prognostic marker in cervical carcinogenesis [8], although there are contradictory results [9]. p53 protein is known as the guardian of the genome, and plays an important role in cellular response to genotoxic stress [10]. This protein acts as a tumor suppression by a variety of mechanisms, including cell cycle arrest, induction of apoptosis, and cellular senescence [11]. Previous studies have evaluated p53 protein expression in cervical intraepithelial lesions and in invasive carcinomas, however the results are contradictory [12-15], making it difficult to establish whether p53 expression is a good biomarker in cervical carcinogenesis. The p21 protein is member of the Cip/Kip family, and is responsible for cell cycle control, blocking the
Expression of E6, p53 and p21 proteins in cells cervical transition from G1-phase to S-phase. The p21 gene is regulated through two different pathways, a p53-dependent pathway and a p53-independent way, through platelet-derived, fibroblast and epidermal growth factors [16, 17]. Reduced expression of p21 protein by immunohistochemistry has been reported in invasive squamous cell carcinoma [18], and it has been suggested as a biomarker. The HPV16 genome can be found in the host cell in episomal, integrated or mixed forms. HPV16 integration into the host genome results in increased levels of E6 and E7 proteins, and this event is considered a critical late-event in cervical carcinogenesis. The prevalence of episomal and integrated forms of HPV16 genome in cervical SIL, varies with severity of disease [19, 20]. In general, the integration of HPV16 genome is considered a late event in cervical carcinogenesis [21].

Several studies have suggested that the immunocytochemical or immunohistochemical detection of p16 [9], p53, p21 [22], cyclin A, cyclin E [23], Ki-67 [24], telomerase [25], E6 [9] and the detection of physical state of HPV16 by ISH [23] in smears or cervical samples may provide useful diagnostic and prognostic information. The aim of this study was to determine the correlation between expression of E6 HPV16, p53 and p21, and the physical state of HPV16 in cervical cytologies without squamous intraepithelial lesions (Non-SIL) and with low grade squamous intraepithelial lesions (LSIL), both with infection by HPV16, to identify possible biomarkers of early cervical lesion.

Materials and methods

Subjects and specimen collection

101 liquid-based cervical cytology samples were collected from women residents in the State of Guerrero, in Southern Mexico. The study population consisted of 50 women diagnosed with Non-SIL and 51 diagnosed with LSIL, all positive to HPV16 by PCR. Exo-endocervical exfoliated cell samples were collected by sampling the ectocervix with an Ayre spatula and endocervix with a cytobrush. Immediately after sample collection smears were prepared for cytomorphological examination through conventional Papanicolaou staining. The remaining cellular content was preserved in liquid base liquid-PREP™ (LPT) and used for immunocytochemistry and ISH. A second sample was collected for DNA extraction. All samples Pap smears were evaluated by an experienced cytopathologist and were classified according to the Bethesda System [26]. All patients signed an informed consent and filled a questionnaire to obtain demographic data and information about gynecological risk factors. This project was approved by the Bioethics Committee of the Autonomous University of Guerrero, Mexico, and all procedures were in accordance with the ethical guidelines of the 2008 Helsinki Declaration.

HPV detection and genotyping

Genomic DNA was extracted from cervical cells by the phenol chloroform method [27]. Purified DNA was used to PCR-amplify a 450 pb conserved region of the HPV L1 gene using consensus primers MY09 and MY11 [28, 29]. The reaction mixtures (50 µl) contained 0.8 µM of each primer, 2 mM MgCl₂, 1X PCR buffer, 150 µM of each dNTP, 1.25 unit of AmpliTaqGold™ (Applied Biosystems, Foster City, CA) and 500 ng of target DNA. DNA was amplified in GeneAmp PCR System 2400 (Applied Biosystems, Foster City, CA), under the following conditions: 95°C, 10 min; 40 amplification cycles (95°C, 1 min; 58°C, 1 min and 72°C, 1 min) and 72°C, 10 min. Integrity of DNA specimens was verified by amplification of a 268 bp region of the human β-globin gene using PC04 and GH20 primers [30]. HPV16 plasmid, and genomic DNA from CaSki and HeLa cells were used as positive controls. Genomic DNA without HPV DNA and water were used as negative controls. For HPV genotyping, amplified PCR products were digested with restriction enzymes BamHI, DdeI, Haelll, Hinfl, PstI, Rsal and Sau3AI (Invitrogen, Carlsbad, CA) and RFLP analysis was performed to identify more than 40 genital types of HPV [31].

Immunocytochemistry

The presence of E6, p53 and p21 proteins was determined by the streptavidin-biotin-peroxidase immunocytochemical method, utilizing the Cytoscan HRP/DAB Cell detection system (Cell Marque Corporation, Hot Springs, AR, USA). The monoclonal antibodies used were anti-E6 (clone C1P5; 1:50; Santa Cruz Biotechnology and Chemicon International, Inc.) anti-p53 (clone DO-7; 1:50; Dako, Carpinteria, CA, USA) and anti-p21 (clone SX118; 1:50; Dako,
Expression of E6, p53 and p21 proteins in cells cervical

Table 1. Expression of E6, p53 and p21 proteins and HPV16 physical state in Non-SIL and LSIL

<table>
<thead>
<tr>
<th></th>
<th>Non-IL</th>
<th>LSIL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=50</td>
<td>n=51</td>
</tr>
<tr>
<td><strong>Expression of E6</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>Mild</td>
<td>27</td>
<td>31</td>
</tr>
<tr>
<td>Moderate</td>
<td>13</td>
<td>17</td>
</tr>
<tr>
<td>Intense</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td><strong>Expression of p53</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>29</td>
<td>58.0</td>
</tr>
<tr>
<td>Positive</td>
<td>21</td>
<td>42.0</td>
</tr>
<tr>
<td><strong>Expression of p21</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>41</td>
<td>82.0</td>
</tr>
<tr>
<td>Positive</td>
<td>9</td>
<td>18.0</td>
</tr>
<tr>
<td><strong>HPV16 Physical state</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Episomal</td>
<td>13</td>
<td>26.0</td>
</tr>
<tr>
<td>Integrated</td>
<td>11</td>
<td>22.0</td>
</tr>
<tr>
<td>Mixed</td>
<td>26</td>
<td>52.0</td>
</tr>
</tbody>
</table>

HPV human papillomavirus, SIL squamous intraepithelial lesion, LSIL low-grade squamous intraepithelial lesion. aFisher exact test. bΧ². Significant value is indicated in bold.

The monolayer smears were digested for 1 minute with proteinase K (1:1000). A drop of test reagent (biotinylated viral DNA) with probes for 13 HR-HPV genotypes (16, 18, 31, 33, 39, 45, 51, 52, 56, 58, 59 and 68) was added to each slide. The slides were denatured for 10 minutes and subjected to hybridization for 20 hours (Hybridizer Dako, Carpinteria, CA, USA). Samples were placed in an astringent solution, incubated with primary streptavidin peroxidase, followed by biotin–tyramide and then secondary streptavidin. The reaction was developed with DAB was added and samples were counterstained with Mayer’s hematoxylin (Merck). Positive reaction was visualized as a brown color inside the nucleus as diffuse (episomal state), punctate (integrated state) or mixed (diffuse and punctate) pattern. SiHa cell lines (HPV-16) which carry integrated HPV16 genome, were used as positive controls; the same cell line without the probe was used as negative control.

Table 1 shows the expression of E6, p53 and p21 proteins and the HPV16 physical state in Non-SIL and LSIL. Table 1 shows the expression of E6, p53 and p21 proteins and the HPV16 physical state in Non-SIL and LSIL samples. The expression of HPV16 E6 protein was significantly higher in LSIL that Non-SIL (p=0.006). We found no significant differences in p53 and p21 expression or HPV16 physical state between Non-SIL and LSIL. Representative images of immunostaining for E6, p53, p21 and in situ hybridization for HPV16 physical state in Non-SIL and LSIL samples are shown in Figure 1.

In situ hybridization

Detection of the viral genome was done with a system of tyramide signal amplification (GenPoint Dako Cytomation, Carpinteria, CA, USA).

Statistical analysis

Statistical analysis was performed using the STATA 10.0 software package (Stat corporation, College Station, TX, USA). Comparison of proteins expression among Non-SIL and LSIL was done by Χ² or Fisher exact test. All the correlations were analyzed by the Fisher exact test. A p value of <0.05 was considerate statistically significant.

Results

We analyzed the physical state of HPV16 and the expression of E6, p53 and p21 proteins in cervical samples from 101 women diagnosed with Non-SIL (50) or LSIL (51). The mean age of the study population was 41.2±9.6 years (range, 25-66 years) for Non-SIL and 36.7±12.5 years (range, 20-66 years) for LSIL. Table 1 shows the expression of E6, p53 and p21 proteins and the HPV16 physical state in Non-SIL and LSIL samples. The expression of HPV16 E6 protein was significantly higher in LSIL than Non-SIL (p=0.006). We found no significant differences in p53 and p21 expression or HPV16 physical state between Non-SIL and LSIL. Representative images of immunostaining for E6, p53, p21 and in situ hybridization for HPV16 physical state in Non-SIL and LSIL samples are shown in Figure 1.
The correlation between expression of E6 and the HPV16 physical state in Non-SIL and LSIL is shown in Table 2. We found a significant correlation between E6 expression and the HPV16 physical state in Non-SIL ($p=0.049$) but not in LSIL ($p=0.335$). The correlation between expression of E6 and p21 and expression of p53 in Non-SIL and LSIL is shown in Table 3. We did not find any correlation between expression of E6 and p21 and expression of p53 in Non-SIL or LSIL.

Discussion

In this study, we analyzed the expression of E6, p53 and p21 proteins and the physical state of HPV16 in Non-SIL and LSIL, both with HPV16 infection.

Several reports have shown the important role of E6 protein in the genesis and development of cervical cancer. The E6 protein from HPV16 is sufficient for the induction and maintenance of cellular transformation [34]. This is mainly due...
Expression of E6, p53 and p21 proteins in cells cervical

Table 2. Correlation between expression of E6 and the HPV16 physical state in Non-SIL and LSIL

<table>
<thead>
<tr>
<th>Physical state</th>
<th>Non-SIL n=50</th>
<th>LSIL n=51</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Episomal</td>
<td>Integrated</td>
<td>Mixed</td>
</tr>
<tr>
<td>Episomal</td>
<td>n</td>
<td>%</td>
<td>n</td>
</tr>
<tr>
<td>Negative</td>
<td>4</td>
<td>30.8</td>
<td>1</td>
</tr>
<tr>
<td>Mild</td>
<td>9</td>
<td>69.2</td>
<td>6</td>
</tr>
<tr>
<td>Moderate</td>
<td>0</td>
<td>0.0</td>
<td>3</td>
</tr>
<tr>
<td>Intense</td>
<td>0</td>
<td>0.0</td>
<td>1</td>
</tr>
</tbody>
</table>

Table 3. Correlation between expression of E6 and p21 and expression of p53 in Non-SIL and LSIL

<table>
<thead>
<tr>
<th></th>
<th>Non-SIL n=50</th>
<th>LSIL n=51</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Negative</td>
<td>Positive</td>
<td></td>
</tr>
<tr>
<td></td>
<td>n</td>
<td>%</td>
<td>n</td>
</tr>
<tr>
<td>Expression of E6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>3</td>
<td>10.3</td>
<td>6</td>
</tr>
<tr>
<td>Mild</td>
<td>19</td>
<td>65.5</td>
<td>8</td>
</tr>
<tr>
<td>Moderate</td>
<td>7</td>
<td>24.2</td>
<td>6</td>
</tr>
<tr>
<td>Intense</td>
<td>0</td>
<td>0.0</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>Positive</td>
<td></td>
</tr>
<tr>
<td></td>
<td>n</td>
<td>%</td>
<td>n</td>
</tr>
<tr>
<td>p21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>24</td>
<td>82.8</td>
<td>17</td>
</tr>
<tr>
<td>Positive</td>
<td>5</td>
<td>17.2</td>
<td>4</td>
</tr>
</tbody>
</table>

SIL squamous intraepithelial lesion, LSIL low-grade squamous intraepithelial lesion. P was calculate using Fisher exact test. Significant value is indicated in bold.

Expression of E6-induced degradation of p53 and p73 by 26S proteasome [7]. The inactivation of p53 compromises the integrity of the cellular genome, causes DNA damage and chromosomal instability, these abnormalities result in increased cell proliferation and tumor development [35-37]. In this work, we found that E6 expression was significantly higher in LSIL that in Non-SIL (p=0.006). These results suggest that elevated E6 expression may be an early marker of cervical cancer progression. To our knowledge few studies have evaluated the E6 expression in precancerous lesion and cervical cancer by immunocytochemistry. However, other cellular proteins with high expression in LSIL have been shown to be useful as early markers in cervical cancer [9, 16, 22, 38].

In this work, we found no significant differences in p53 expression between Non-SIL and LSIL. We detected the p53 expression in 42% Non-SIL and 33.3% LSIL samples. In a previous study, Graspa et al analyzed the expression of p53 in normal cervical tissue and LSIL [39], however, in contrast with our data, they did not detect p53 expression in either Non-SIL or LSIL samples. Ours results can be explained by the fact that all Non-SIL samples are positive to HPV16 infection, whereas in their work, samples where negative to HPV16 because this infection could represent a stress response to viral infection [40]. Furthermore p53 expression could occur as a result of p53 stabilization by E6 protein binding [41, 42].

As a consequence of the E6-mediated p53 inactivation, p21 gene transcription is inhibited [43], also E7 oncoprotein from high risk HPV, can target p21 for degradation during carcinogenesis [44]. In this work, we found no significant differences in p21 expression between Non-SIL and LSIL. p21 protein was detected 18% Non-SIL samples and 11.8% LSIL samples. In contrast to our results, previous reports found p21 expression in 15% of samples from normal cervical tissue without HPV and in 100% cases of NICI (equivalent to LSIL) [18]. These differences can be explained by the number of samples and by HPV16 infection. Also, the inactivation of p21 via reduced expression has been reported in various human tumors [45].
Our results show HPV16 integration in 22% of Non-SIL and 19.6% of LSIL. These results suggest that viral integration is an early event in the progression of cervical cancer. Furthermore, it has been demonstrated that cell populations with integrated HPV16 posses a selective growth advantage compared to cells that maintain HPV16 viral genomes as episomes [46]. We found a significant correlation between E6 expression and the HPV16 physical state in Non-SIL (p=0.049). Integration of HPV16 into the host genome can results in elevated expression levels of E6 and E7 viral oncoproteins, with subsequent interaction between these proteins and the cell cycle machinery [19, 20]. In agreement with these observations, we found that the E6 expression level was higher in HPV16 integrated genome samples.

In conclusion, our results suggest that high E6 expression is an early event of cervical carcinogenesis and perhaps can be used as an early marker. However, compared with previous reports our study includes small number of samples; therefore, it is necessary to validate our results in a larger population. Moreover, including high grade squamous intraepithelial lesions (HSIL) in the study will provide important information to validate the usefulness of E6 expression as an early marker in cervical cancer progression.

Acknowledgements

Diana Karen Jiménez Tagle was recipient of a master fellowship from Consejo Nacional de Ciencia y tecnología (CONACyT), belongs to Programa de Maestría en Ciencias Biomédicas, UAG. We would like to thank to Programa de Fortalecimiento Académico del Posgrado de Alta Calidad of CONACyT.

Address correspondence to: Dr. Luz del Carmen Alarcón Romero, Laboratorio de Investigación en Citopatología e Histoquímica, Unidad Académica de Ciencias Químico Biológicas Universidad Autónoma de Guerrero Avenida Lázaro Cárdenas, Ciudad Universitaria, Chilpancingo, Guerrero, México. C.P. 39090, México. Tel: +52(747)4710901; E-mail: luzdelcarmen49@yahoo.com.mx

References

Expression of E6, p53 and p21 proteins in cells cervical


Expression of E6, p53 and p21 proteins in cells cervical


